Application of the Benefit-Risk Action Team (BRAT) Framework in Pharmaceutical R&D: Results From a Pilot Program

Drug Information Journal

Volumn 46, Issue 6, 2012, Pages 736-743

  Noel, Rebecca ^a   Hermann, Richard ^b   Levitan, Bennett ^c   Watson, Douglas J ^d   van Goor, Kristin ^e  

^a ELI LILLY AND COMPANY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Pharmaceutical Research and Manufacturers of America   (United States)

Author keywords

benefit risk; drug development; outcome assessment; pharmacovigilence; risk assessment

Indexed keywords

ARTICLE; BENEFIT RISK ACTION TEAM; CONCEPTUAL FRAMEWORK; DECISION MAKING; DRUG MANUFACTURE; HUMAN; PHARMACY BENEFIT MANAGER; PILOT STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESEARCH; RISK BENEFIT ANALYSIS;

EID: 84871937059     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512458908     Document Type: Article

References (15)

1. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Baciu AStratton KBurke SP, ed. Washington, DC: The National Academies Press; 2007:.
2. Breckenridge A.Regulatory challenges, reimbursement, and risk-benefit assessment.Clin Pharmacol Ther. 2010;88 (2): 153-154.
3. Coplan PM,Noel RA,Levitan BS,Ferguson J,Mussen F.Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.Clin Pharmacol Ther. 2011;89 (2): 312-315.
4. Levitan BS,Andrews EB,Gilsenan A, et al.Application of the BRAT framework to case studies: observations and insights.Clin Pharmacol Ther. 2011;89 (2): 217-224.
5. Walker S,McAuslane N,Liberti L,Salek S.Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.Clin Pharmacol Ther. 2009;85 (3): 241-246.
6. Brass EP,Lofstedt R,Renn O.Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment.Clin Pharmacol Ther. 2011;90 (6): 791-803.
7. The European Medicines Agency. Benefit-Risk Methodology Project. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/07/WC500109477.pdf. Published March 2009. Accessed March 12, 2012.
8. CIRS. Benefit-risk assessment. http://cirsci.org/benefit-risk. Accessed April 1, 2012.
9. Innovative Medicines Initiative. Protect. http://www.imi.europa.eu/content/protect. Published 2010. Accessed May 27, 2012.
10. PDUFA reauthorization performance goals and procedures fiscal years 2013 through 2017. http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf. Published 2012. Accessed August 16, 2012.
11. KobersteinW. Janet Woodcock-CDER, safety, and the cutting edge. http://www.lifescienceleader.com/magazine/past-issues3/item/3827-janet-woodcock-%E2%80%94-cder-safety-and-the-cutting-edge. Accessed August16, 2012.
12. FDA working with patients to explore benefit/risk: opportunities and challenges. Meeting notice. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm298136.htm. Accessed April 16, 2012.
13. Cardiovascular and Renal Drugs Advisory Committee for rivaroxaban. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM272005.pdf. Published September 2011. Accessed April 1, 2012.
14. Markowitz M,Levitan B,Jing Fu D, et al.Benefit-risk assessment of maintenance therapy in schizophrenia comparing long-acting injectable (LAI) paliperidone palmitate with paliperidone ER. Presented at: Annual Meeting of the American Psychiatric Association; Honolulu, HI.
15. Holden WL,Juhaeri J,Dai W.Benefit-risk analysis: a proposal using quantitative methods.Pharmacoepidemiol Drug Saf. 2003;12 (7): 611-616.